Henry Schein (HSIC) beat fourth-quarter profit estimates Tuesday on strong dental and medical equipment sales, driving shares higher in pre-market trading.
The healthcare distributor’s performance signals continued recovery in dental practices and medical facilities, supporting investor confidence in the sector’s post-pandemic rebound.
Key Takeaways
- Q4 EPS of 1.34 beat estimates by 0.04
- Revenue hit 3.44 billion, up 7.7% year-over-year
- Specialty products sales surged 14.6% to 422 million
Market reaction & context
Henry Schein reported earnings per share of 1.34 for the fourth quarter, beating analyst consensus estimates of 1.30 by four cents 1. Revenue reached 3.44 billion, surpassing Wall Street expectations of 3.34 billion and representing 7.7% year-over-year growth 2.
The results outpaced broader healthcare distribution sector performance, with the company’s specialty products division leading growth. Global specialty products, which includes dental implants and biomaterials, posted particularly strong results with 14.6% sales growth to 422 million 3.
Detailed analysis
The dental equipment segment drove much of the quarter’s outperformance, benefiting from continued recovery in dental practice volumes and procedure rates. Medical equipment sales also contributed to the beat, reflecting steady demand from healthcare facilities 4.
However, margin contraction tempered some of the positive results, with analysts noting pressure on profitability despite strong top-line growth 5. The company’s technology services division also contributed to overall performance gains.
Outlook
Henry Schein forecast annual profit largely in line with Wall Street expectations, signaling management’s cautious optimism about 2026 prospects 6. The company expects continued strength in its specialty products division, particularly dental implants and endodontics products.
Management highlighted the resilience of dental and medical equipment demand, with dental implant and endodontics products driving the specialty segment’s strong performance 7.
Conclusion
Henry Schein’s fourth-quarter results demonstrate the healthcare distributor’s ability to capitalize on recovering dental practice volumes and steady medical facility demand. While margin pressures remain a concern, the company’s diversified product portfolio and strong specialty products growth provide a solid foundation for 2026.
The earnings beat reinforces the investment thesis around healthcare infrastructure recovery and positions Henry Schein well among healthcare distribution peers.
Not investment advice. For informational purposes only.
References
1MarketBeat (2026-02-24). “Henry Schein (NASDAQ:HSIC) Releases Earnings Results, Beats Estimates by 0.04 EPS”. Retrieved February 24, 2026.
2StockStory (2026-02-24). “Henry Schein’s (NASDAQ:HSIC) Q4 CY2025 Sales Beat Estimates”. Retrieved February 24, 2026.
3Investing.com (2026-02-24). “Henry Schein beats estimates on earnings and revenue”. Retrieved February 24, 2026.
4Reuters (2026-02-24). “Henry Schein beats quarterly profit estimates on strong dental, medical equipment sales”. Retrieved February 24, 2026.
5Zacks (2026-02-24). “HSIC Q4 Earnings & Revenues Beat Estimates, Margins Down”. Retrieved February 24, 2026.
6Yahoo Finance (2026-02-24). “Henry Schein beats quarterly profit estimates on strong dental equipment sales”. Retrieved February 24, 2026.
7TradingView (2026-02-24). “Henry Schein beats quarterly profit estimates on strong dental, medical equipment sales”. Retrieved February 24, 2026.